| Literature DB >> 28854772 |
Hiroki Tanaka1, Shimpei Matsusaki1, Youichirou Baba2, Yoshiaki Isono1, Tomohiro Sase1, Hiroshi Okano1, Tomonori Saito1, Katsumi Mukai1, Tetsuya Murata2, Hiroki Taoka3.
Abstract
BACKGROUND/AIMS: It is sometimes difficult to distinguish between malignant and benign biliary strictures using imaging studies alone, and pathological diagnosis is necessary. The aim of this study was to determine the usefulness of endoscopic transpapillary tissue sampling and factors predictive of diagnostic accuracy.Entities:
Keywords: Biliary tract neoplasms; Endoscopic retrograde cholangiography; Obstructive janudice; Pancreatic neoplasms
Year: 2017 PMID: 28854772 PMCID: PMC5903074 DOI: 10.5946/ce.2017.082
Source DB: PubMed Journal: Clin Endosc ISSN: 2234-2400
Patients’ Characteristics
| Male: Female | 79: 57 |
| Age (yr) | Mean 74 (45–94) |
| Final diagnosis | |
| Pancreatic cancer | 55 |
| Extrahepatic cholangiocarcinoma | 35 |
| Gallbladder cancer | 25 |
| Intrahepatic cholangiocarcinoma | 13 |
| Ampullary carcinoma | 1 |
| Postoperative recurrences | 5 |
| Pancreatic neuroendocrine carcinoma | 1 |
| Metastatic cancer | 1 |
Sensitivity of Endoscopic Transpapillary Tissue Sampling
| (a) | Forceps biopsy | 80/123 |
| 65.0% | ||
| (b) | Brush cytology | 55/111 |
| 49.5% | ||
| (c) | Aspiration cytology | 36/78 |
| 46.2% | ||
| (d) | ENBD cytology | 7/32 |
| 21.9% | ||
| (e) | Combination of each procedure | 99/136 |
| 72.8% |
P<0.05: (a) vs. (e), (b) vs. (e), (c) vs. (e), (d) vs. (e).
ENBD, endoscopic nasobiliary drainage.
Negative Results on Endoscopic Transpapillary Tissue Sampling
| Methods for diagnosis | |
|---|---|
| Pancreatic cancer ( | EUS-FNA 4, liver biopsy 1, duodenal biopsy 2 |
| Imaging studies 7 | |
| Intrahepatic cholangiocarcinoma ( | Liver biopsy 2 |
| Imaging studies 2 | |
| Gallbladder cancer ( | Imaging studies 4 |
| Extrahepatic cholangiocarcinoma ( | Imaging studies 2 |
| Postoperative recurrences ( | Liver biopsy 1 |
| Imaging studies 1 | |
| Pancreatic neuroendocrine carcinoma ( | EUS-FNA 1 |
| Ampullary carcinoma ( | Duodenal biopsy 1 |
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
Sensitivity of Endoscopic Transpapillary Tissue Sampling by Final Diagnosis
| Forceps biopsy | Brush cytology | Aspiration cytology | ENBD cytology | Total | |
|---|---|---|---|---|---|
| Pancreatic cancer ( | 30/51 | 23/47 | 11/29 | 1/9 | 38/55 |
| 58.8% | 48.9% | 37.9% | 11.1% | 69.1% | |
| Extrahepatic cholangiocarcinoma ( | 27/32 | 16/27 | 11/21 | 2/10 | 32/35 |
| 84.4% | 59.3% | 52.4% | 20.0% | 91.4% | |
| Gallbladder cancer ( | 14/22 | 11/22 | 11/19 | 3/9 | 14/25 |
| 63.6% | 50.0% | 57.9% | 33.3% | 56.0% | |
| Intrahepatic cholangiocarcinoma ( | 6/11 | 3/11 | 2/6 | 1/3 | 8/13 |
| 54.5% | 27.3% | 33.3% | 33.3% | 61.5% |
ENBD, endoscopic nasobiliary drainage.
Sensitivity of Endoscopic Transpapillary Tissue Sampling by Final Diagnosis (Biliary-Origin Lesions vs. Extrabiliary-Origin Lesions)
| Biliary-origin lesions ( | Extrabiliary-origin lesions ( | ||
|---|---|---|---|
| Forceps biopsy | 27/32 | 53/91 | 0.00923 |
| 84.4% | 58.2% | ||
| Brush cytology | 16/27 | 39/84 | 0.28 |
| 59.3% | 46.4% | ||
| Aspiration cytology | 11/21 | 25/57 | 0.61 |
| 52.4% | 43.9% | ||
| ENBD cytology | 2/10 | 5/22 | 1.00 |
| 20.0% | 22.7% | ||
| Total | 32/35 | 67/101 | 0.00378 |
| 91.4% | 66.3% |
ENBD, endoscopic nasobiliary drainage.
Causes of False-Negative Results
| Inadequate material | Insufficient material | Normal bile duct epithelium | Inflammatory atypia/Reactive change | |
|---|---|---|---|---|
| Forceps biopsy | 4/43 | 5/43 | 33/43 | 3/43 |
| 9.3% | 11.6% | 76.7% | 7.0% | |
| Brush cytology | 3/56 | 4/56 | 54/56 | 0/56 |
| 5.4% | 7.1% | 96.4% | 0% | |
| Brush cytology | 4/42 | 1/42 | 38/42 | 0/42 |
| 9.5% | 2.4% | 90.5% | 0% | |
| Aspiration cytology | 1/25 | 1/25 | 23/25 | 2/25 |
| 4.0% | 4.0% | 92.0% | 8.0% |
Sensitivity by Cancer Infiltrative Pattern
| Inf a (α), b (β) | Inf c (γ) | ||
|---|---|---|---|
| Biliary-origin lesions ( | 14/14 | 4/6 | 0.079 |
| 100% | 66.7% | ||
| Extrabiliary-origin lesions ( | 7/10 | 4/9 | 0.369 |
| 70.0% | 44.4% | ||
| Total ( | 21/24 | 8/15 | 0.027 |
| 87.5% | 53.3% |
Sensitivity by Cancer Stromal Volume
| Med, int | Sci | ||
|---|---|---|---|
| Biliary-origin lesions ( | 13/14 | 4/6 | 0.20 |
| 92.9% | 66.7% | ||
| Extrabiliary-origin lesions ( | 6/9 | 5/10 | 0.65 |
| 66.7% | 50.0% | ||
| Total ( | 19/23 | 9/16 | 0.15 |
| 82.6% | 56.3% |